The promise of directing the immune system to precisely target malignancies is extraordinary, and clinical successes inspire for broader application. Yet, the path from concept to clinical reality remains complex, with challenges in manufacturing, delivery, long-term efficacy and safety. This meeting will bring together key opinion leaders, experts, and stakeholders to navigate through the evolving landscape of CAR T therapies, focusing on:
- Clinical successes and challenges
- The management of toxicities
- Mechanisms and strategies for long-term safety and efficacy
- Recent scientific innovations and new indications
Building on the success of previous editions, the upcoming meeting will feature a comprehensive program showcasing the latest
- Scientific advances
- Clinical developments
- Real-world applications
We look forward to insightful discussions, meaningful connections, and continued progress in advancing patient care.
For those unable to attend in-person, the meeting will also be available virtually, with most of the sessions livestreamed via the virtual meeting platform.
Whether you’re a physician, scientist, industry representative, nurse, data manager, pharmacist, or patient advocate, this meeting offers a unique opportunity to engage with the forefront of CAR T-cell therapy development.
Format
This is a hybrid meeting, which can be attended in person or virtually.
The emphasis lies on in-person participation in the program, but most sessions will be live-streamed via a virtual platform for those who can only follow the program remotely.
Target audience
The target audience is:
- Hematologists
- Oncologists
- Physicians
- Nurses
- Data managers
- Supply chain managers
- Patient organisation representatives
